About Bausch & Lomb
Bausch & Lomb is a publicly listed company based in Bridgewater (United States) founded in 1853 by John Jacob Bausch and Henry Lomb, and was acquired by Bausch Health in May 2013. It operates as an ophthalmic pharmaceuticals and instruments are developed for eye care. The company has 13,500 employees. Bausch & Lomb has completed 12 acquisitions, including AcuFocus, Doctor's Allergy Formula and ELIOS Vision. Its website bausch.com draws about 175 thousand monthly visits. Its Indian entity Bausch & Lomb India Private Limited reported revenue of ₹274 Cr. Its focus areas include Traditional Pharmaceuticals and Traditional Medical Devices. Its competitors include Merck, Roivant Sciences, AbbVie, Gilead and Lilly and 5 more; 2 of its 10 listed competitors have raised funding.
Company details
Bausch Lomb was founded in 1853 and is headquartered in Bridgewater, United States. Focus is placed on the ophthalmology sector, where pharmaceutical products, contact lenses, lens care items, eye care solutions, over-the-counter offerings, and surgical devices are developed and distributed. Operations encompass research, manufacturing, and global supply of these instruments and products to support eye health and vision correction needs.
- Headquarters Bridgewater, United States
- Employees 13,500
- Founders John Jacob Bausch, Henry Lomb
- Stage Public
- SectorsHealthcare
- Website category Health
- Email••••••••
- Phone•••• ••••
- Website bausch.com
- Social LinkedIn X Facebook Instagram
- Acquired by Bausch Health (May 2013)
- Legal Name Bausch + Lomb Corporation
- Annual Revenue₹274 Cr
FY 2025 · -7% YoY
- Net Profit₹2.15 Cr
FY 2025 · 1% margin
- EBITDA₹6.82 Cr
FY 2025 · 2% margin
- InvestorsBausch Health
& 2 more
- Employee Count13,500
- Investments & AcquisitionsAcuFocus
& 11 more
- Acquired byBausch Health
(May 2013)
Associated legal entities of Bausch & Lomb
Bausch & Lomb is associated with 2 registered companies on The Company Check; the primary company is Bausch & Lomb India Private Limited. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Bausch & Lomb India Private Limited CIN U46497DL2000PTC105978 | Active | 30 May 2000 | New Delhi, Delhi | ₹274 Cr | – | 3 | View details |
| Bausch & Lomb India Private Limited CIN U33119DL2000PTC105978 | Active | 30 May 2000 | New Elhi, Delhi, India | – | – | – | View details |
Funding Insights of Bausch & Lomb
- Total Rounds 2
- First Round $973,000
(Jul 2015)
- Investors Count 2
All 2 funding rounds of Bausch Lomb with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
3 investors in total: 3 institutional.
Investors in Bausch & Lomb
Bausch & Lomb has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Bausch Health, IMRF and RGE.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | imrf.org | - | |
- | – | rge.com | - | |
Therapeutics for multiple diseases including dermatology and neurology are developed. | 1960 | bauschhealth.com | Laval, Canada |
Investor details for Bausch Lomb
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Bausch & Lomb India Private Limited (Bausch & Lomb)
Bausch & Lomb India Private Limited is the primary company behind Bausch & Lomb. The board of Bausch & Lomb India Private Limited currently have 2 directors; the longest-serving is Sanjay Bhutani, appointed in 2009. 18 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sanjay Bhutani DIN 00931832 | Managing Director | 26 Jun 2009 | 17 yrs 3 mo | Bausch & Lomb India Private Limited |
| Nidhish Moghe DIN 07018421 | Director | 26 Nov 2014 | 11 yrs 10 mo | Bausch & Lomb India Private Limited |
People of Bausch & Lomb
14 people are tracked at Bausch & Lomb (10 in leadership, 4 in team); the tracked headcount is 13,500.
| Name | Role | Group |
|---|---|---|
John Jacob Bausch | Co-Founder | Leadership |
Henry Lomb | Co-Founder | Leadership |
Allison Ryan | Executive Director | Leadership |
Brent Saunders | Chief Executive Officer | Leadership |
Yang Yang | President, Vision Care | Leadership |
Sam Eldessouky | EVP & CFO | Leadership |
Andrew Stewart | President, Global Pharmaceuticals & International Consumer | Leadership |
Yehia Hashad | EVP, Research & Development & Chief Medical Officer | Leadership |
Luc Bonnefoy | President, Surgical | Leadership |
Bob Bailey | EVP & Chief Legal Officer | Leadership |
John Ferris | EVP, Consumer | Team |
Kelly Tehan | Senior Financial Analyst | Team |
Asli Gevgilili | EVP & CHRO | Team |
Francisco Alba-Bueno | Sr Principal Engineer | Team |
Complete people profiles for Bausch & Lomb
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Bausch & Lomb
Bausch & Lomb is a publicly listed company on the NYSE with ticker symbol BLCO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date10 May 2022
- Listed onTSX: BLCO
- Listed entityBausch + Lomb Corporation
- Exchange sectorHealth technology
- ISINCA0717051076
- Share price$15.81 (-1.62% on the day) · 2026-10-13
- Market capitalisation$5.65B
- EPS (diluted, trailing year)$-0.48
- Volume (last session)757,500
Financials of Bausch & Lomb
Figures of Bausch & Lomb India Private Limited, the primary company behind Bausch & Lomb, for FY 2025. Revenue was ₹274 Cr (-7% year on year). Net profit was ₹2.15 Cr (1% margin). EBITDA was ₹6.82 Cr (2% margin). Revenue has grown at a compounded annual rate of +8% over three years and +3% over five years.
- ₹274 CrRevenue · FY 2025 · -7% YoY
- ₹2.15 CrNet profit · 1% margin
- ₹6.82 CrEBITDA · 2% margin
- ₹33.00 CrPaid-up capital
- +8%Revenue CAGR, 3 years
- +3%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $5.10B | -$360.0M | $609.0M |
| 2024 | $4.79B | -$317.0M | $642.0M |
| 2023 | $4.15B | -$260.0M | $586.0M |
| 2022 | $3.77B | $6.0M | $599.0M |
| 2021 | $3.77B | $182.0M | $761.0M |
Balance sheet, profit and loss, cash flow and ratios of Bausch & Lomb India Private Limited are on its company page.
Detailed financial statements for Bausch & Lomb
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Bausch & Lomb
Bausch & Lomb has strategically engaged in corporate development activities, having acquired 12 companies. Notable acquisitions include AcuFocus, Doctor's Allergy Formula and ELIOS Vision.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapeutics for ophthalmological disorders, including glaucoma treatments, are developed. | whitecapbiosciences.tcc.mode | United States | 2015 | Jan 2025 | •••• | |
Excimer laser technology is applied to develop glaucoma therapy devices. | eliosvision.com | Los Angeles, United States | 2019 | Dec 2024 | •••• | |
Corneal diagnostic tools and technologies are developed and marketed. | trukera.com | – | 0 | Jul 2024 | •••• | |
Xiidra is marketed by Bausch + Lomb for dry eye treatment. | xiidra.com | – | 2013 | Jun 2023 | $2.5B | |
Developer of small aperture technology-based ophthalmic devices | acufocus.com | Irvine, United States | 2001 | Jan 2023 | •••• | |
US-based, private pharma company that develops products for Dry Eye Disease and Ocular Surface Disease | paragonbioteck.com | Portland, United States | 2009 | Nov 2022 | •••• | |
Sterile injectables are developed and commercialized by Eton Pharmaceuticals. | etonpharma.com | Barrington, United States | 2013 | Feb 2019 | •••• | |
Diagnostics for ocular allergies are developed using regional allergen panels. | drsallergyformula.com | Norcross, United States | 2013 | Oct 2015 | •••• | |
Femtosecond and excimer lasers for ophthalmology are designed and produced. | technolaspv.com | Munich, Germany | 2008 | Nov 2012 | •••• | |
Eye care pharmaceutical company | istavision.com | Irvine, United States | 1992 | Mar 2012 | $500M |
Complete acquisition details for Bausch Lomb
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Bausch & Lomb
15 dated milestones of Bausch & Lomb across 172 years, from founding to its latest funding, stage changes and deals.
- Founded Bausch & Lomb is founded.
- Acquisition Acquires ISTA Pharmaceuticals.
- Acquisition Acquires Technolas Perfect Vision.
- Exit Acquired by Bausch Health.
- Funding First funding round of $973K.
- Acquisition Acquires Doctor's Allergy Formula.
- Acquisition Acquires Eton Pharmaceuticals.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Paragon BioTeck.
- Acquisition Acquires AcuFocus.
- Funding Latest funding round, Post-IPO,.
- Acquisition Acquires Xiidra.
- Acquisition Acquires Trukera.
- Acquisition Acquires ELIOS Vision.
- Acquisition Acquires Whitecap Biosciences.
Competitors of Bausch & Lomb
Bausch & Lomb has 10 listed competitors in our database, 2 of them funded. They include Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| merck.com | 1891 | Kenilworth, United Kingdom | – | 781 | Pharmaceutical products are manufactured and marketed worldwide. | |
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| abbvie.com | 2012 | Chicago, United States | – | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | |
| gilead.com | 1987 | Foster, United States | – | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | |
| lilly.com | 1876 | United States | – | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. | |
| vrtx.com | 1989 | United States | – | 5,400 | Developer of drugs for the treatment of multiple disorders | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. | |
| roche.com | 1896 | Basel, Switzerland | – | 2,382 | Pharmaceuticals and diagnostics kits are developed for various diseases. | |
| unither.com | 1998 | Silver Spring, United States | – | 1,168 | Treatments for chronic and life-threatening diseases are developed and commercialized. | |
| ascendispharma.com | 2007 | Hellerup, Denmark | $108.7M | 573 | Long-acting prodrug therapies are developed for endocrine and rare diseases. |
Detailed competitors of Bausch Lomb
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Bausch & Lomb
The website of Bausch & Lomb (bausch.com) receives about 175.4K visits a month and ranks #271,734 among all websites worldwide, #9,257 in Health.
- Monthly visits175.4K
▲ 0.7% vs previous month
- Unique visitors91.1K
per month
- Global rank#271,734
among all websites
- Category rank#9,257
Health · Health
- Bounce rate44%
- Pages per visit1.6
- Average visit26 sec
- DevicesDesktop 38% · Mobile 62%
Websites whose visitors overlap most with Bausch & Lomb. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| alcon.com | 100% | 171K | #286,128 | View details | |
| acuvue.com | 100% | – | #41,837 | View details | |
| allaboutvision.com | 99% | 1.1M | #61,292 | View details | |
| coopervision.com | 86% | – | #81,803 | View details | |
| ocuvite.com | 85% | – | #3,106,860 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Bausch & Lomb
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Traditional Health & Nutrition
10 companies that operate in the same segment as Bausch & Lomb (Traditional Health & Nutrition), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Manufacturer of generics formulations | 2002 | Bridgewater, New Jersey, United States | – | USD 3.02 B | 8,300 | |
Biosimilar therapeutics are developed for oncology and autoimmune diseases. | 2010 | Redwood City, California, United States | USD 143.62 M | USD 42.17 M | 228 | |
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 89.42 M | 962 | |
Generic pharmaceuticals are manufactured by Teva Pharmaceuticals. | 1901 | Petah Tikva, Central District, Israel | USD 500 M | USD 18.74 B | 51,792 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | – | USD 508.93 M | 5,180 | |
Pharmaceutical products are developed and marketed globally. | 2009 | Montville, New Jersey, United States | USD 155.92 M | – | – | |
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | – | USD 6.21 B | 25,870 | |
Pharmaceutical company engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations | 1991 | Delhi, Delhi, India | USD 367.2 M | USD 1.52 B | 21,320 | |
Generics, biosimilars, APIs, and vaccines are manufactured by Wockhardt. | 1967 | Mumbai, Maharashtra, India | – | USD 353.53 M | 3,410 | |
Branded formulations, APIs, and biosimilars are manufactured. | 1944 | Mumbai, Maharashtra, India | – | USD 232.56 M | 3,330 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bausch & Lomb
Complete news archive for Bausch Lomb
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bausch & Lomb
Bausch & Lomb was founded in 1853 and raised its 1st funding round 162 years after it was founded.
Bausch & Lomb is headquartered in Bridgewater, United States. It is registered at Bridgewater, New Jersey, United States.
Bausch & Lomb has 13,500 employees.
The primary company behind Bausch & Lomb, Bausch & Lomb India Private Limited, reported revenue of ₹274 Cr for FY 2025, down 7% year on year.
Bausch Lomb was founded in 1853 and is headquartered in Bridgewater, United States. Focus is placed on the ophthalmology sector, where pharmaceutical products, contact lenses, lens care items, eye care solutions, over-the-counter offerings, and surgical devices are developed and distributed. Operations encompass research, manufacturing, and global supply of these instruments and products to support eye health and vision correction needs.
Bausch & Lomb's top competitors include Merck, Roivant Sciences and AbbVie.
Yes, Bausch & Lomb is publicly traded on NYSE under the ticker symbol BLCO.
Bausch & Lomb has made 12 acquisitions, including AcuFocus, Doctor's Allergy Formula, and ELIOS Vision.
Bausch & Lomb has 3 investors. Key investors include Bausch Health, IMRF, and RGE.
Bausch & Lomb operates through Bausch & Lomb India Private Limited.
Yes. Bausch & Lomb was acquired by Bausch Health in May 2013.
The legal entities of Bausch & Lomb currently have 3 directors, including Sanjay Bhutani, Nidhish Moghe, Rahul Agarwal.